Microphthalmia Transcription Factor, MiTF antibody
- Known as:
- Microphthalmia Transcription Factor, MiTF (anti-)
- Catalog number:
- Mob462-S
- Product Quantity:
- 0.1ml
- Category:
- -
- Supplier:
- Diagnostic Biosystems
- Gene target:
- Microphthalmia Transcription Factor MiTF antibody
Related genes to: Microphthalmia Transcription Factor, MiTF antibody
- Gene:
- MITF NIH gene
- Name:
- melanocyte inducing transcription factor
- Previous symbol:
- WS2A, WS2
- Synonyms:
- MI, bHLHe32
- Chromosome:
- 3p13
- Locus Type:
- gene with protein product
- Date approved:
- 1993-10-27
- Date modifiied:
- 2019-04-23
Related products to: Microphthalmia Transcription Factor, MiTF antibody
Related articles to: Microphthalmia Transcription Factor, MiTF antibody
- To investigate the clinicopathological features of tuberous sclerosis complex (TSC)-associated multifocal micronodular pneumocyte hyperplasia (MMPH) and the mutation status of TSC1/TSC2 genes. A retrospective analysis was conducted on 8 MMPH cases diagnosed at Shanghai Pulmonary Hospital Affiliated to Tongji University from September 2020 to August 2024. Clinical information and imaging findings of these cases were collected. Histopathological analysis and next-generation sequencing (NGS) were performed. Among the 8 patients, there were 4 males and 4 females, aged 44 (36, 50) years old. None of them had a definite family history of TSC. Only 1 patient presented with respiratory symptoms at the time of consultation. Four patients had TSC-related cutaneous lesions. Two had shagreen patches, 1 had hypomelanotic macules, and 1 had hypomelanotic macules combined with fibrous plaques on the scalp and angiofibromas. Three patients themselves or their first-degree relatives had a history of epilepsy. Five patients themselves or their first-degree relatives had liver/kidney cysts or a surgical history of renal angiomyolipoma. Computerized tomography scans showed multiple ground-glass nodules in both lungs, with an average diameter of 10.5 (8.5, 11.0) mm. Six cases were diagnosed via surgical resection, and 2 via transbronchial cryobiopsy. Intraoperative frozen sections of the 6 surgically resected cases were all misdiagnosed as early-stage lung adenocarcinoma (including adenocarcinoma in situ, minimally invasive adenocarcinoma, and invasive non-mucinous adenocarcinoma), but the diagnosis was corrected to MMPH postoperatively. One of these 6 cases was concurrent with a benign perivascular epithelioid cell tumor (PEComa). Microscopically, MMPH was characterized by multifocal proliferation of type Ⅱ alveolar epithelial cells, which showed bland cellular morphology without atypia or invasive growth. For the case concurrent with PEComa, clear epithelioid cells were observed growing in nests or sheets. Immunohistochemically, the proliferative epithelial cells were positive for TTF-1 and showed low expression of Ki-67. PEComa cells were positive for Melan A and MiTF. NGS showed that TSC1 mutations were detected in 6 cases, TSC2 mutation in 1 case (which also had a concurrent class Ⅲ missense mutation of BRAF G466E), and no mutation in 1 case, with an overall mutation detection ratio is 7/8. No other lung cancer-related driver-gene variations were found in any case. Follow-up data were available for 8 patients. During the follow-up, 1 patient developed scattered thin-walled lucencies in both lungs, but no pathological examination was performed. All patients had a favorable overall survival status, follow-up time was 14.0(9.5,47.0) months. MMPH is a rare, benign TSC-associated pulmonary lesion, often presenting as multiple ground-glass nodules in both lungs. It can be easily misdiagnosed as early-stage lung adenocarcinoma. The diagnosis requires a comprehensive judgment based on clinical data, imaging findings, histopathology, and TSC1/TSC2 gene mutation results. - Source: PubMed
Zhang P YWu C YWu WXie H KHou L KHuang YDong Z WLi S LXie X F - Neuroendocrine neoplasms (NENs) are increasingly recognized to have a hereditary predilection, yet the prevalence and clinical relevance of pathogenic germline variants (PGVs) in unselected NEN patients remain poorly defined. This prospective, multicenter study aimed to evaluate the prevalence and clinical utility of PGVs through universal multi-gene panel testing in a diverse cohort of NEN patients. - Source: PubMed
Publication date: 2026/06/04
Abidoye OluseyiGolafshar MichaelKunz KatieEslinger CodyElsabbagh ZaidAlheraki Samee ZaneAlsulaiman AbdullahKlint MargaretEsplin EdwardNussbaum Robert LStarr JasonAhn DanielBekaii-Saab TaniosHalfdanarson ThorvardurSamadder Niloy JewelSonbol Mohamad Bassam - Clear cell renal cell carcinoma (ccRCC)-derived extracellular vesicles (EVs) play a pivotal role in myeloid cell differentiation toward immunosuppressive phenotypes, yet the underlying mechanisms remain poorly understood. Through integrated single-nucleus RNA sequencing, EV proteomics, and phenotype validation, we identified NOD1, a pattern recognition receptor (PRR), as a critical mediator of EV-driven macrophage differentiation. Clinically, NOD1 overexpression in ccRCC tissues correlated with increased immunosuppressive macrophage infiltration, immune checkpoint inhibitors (ICIs) therapy resistance, and poor prognosis. Mechanistically, ccRCC-EVs enriched with SCRIB, a Rho GTPase activator, triggered sustained NOD1 activation in macrophages via Rho GTPase signalling. Crucially, NOD1 signalling converged on interferon regulatory factor 4 (IRF4), whose expression might be dynamically regulated through NF-κB activation and MITF suppression. Furthermore, inhibition of NOD1 promotes the therapeutic effect of ICIs in vivo. Our findings unveil a novel EV-mediated immune evasion mechanism in ccRCC and propose the SCRIB-NOD1-IRF4 axis as a therapeutic target to restore anti-tumour immunity. - Source: PubMed
Pan Xiu-WuLi Mu-ChenYang Tian-YueLiu Yi-FanZhou Jia-LinTang Yi-FanZheng Hong-FengLiu Jian-GuiLiu Zi-ChangMa Wen-JieLi Wen-YanGong Zi-XuanZhang ShunZhang Hang-BiaoLu Bing-NanYao Yun-TaoLyu Dong-HaoZhu Guan-YuZong Yuan-BoYao Han-LinZhang Ai-PingZeng JinXiong Si-TuDong Ke-QinZhou WangFu BinCui Xin-Gang - Phytochemical investigation of the edible fungus (Poria cum Radix Pini, PRP) led to the isolation and identification of 40 lanostane-type triterpenoids (LTDs), including seven new LTDs. Six LTDs (, , , , , ) exhibited antimelanogenic activity in B16F10 cells and zebrafish. Structure-activity relationship analysis revealed that an α-oriented hydroxyl at C-3, absence of C-16 hydroxyl, and free C-3 hydroxyl are critical for high activity. LTD suppressed melanogenesis by inhibiting the ERK pathway, downregulating MITF and tyrosinase. Molecular docking and dynamics predicted stable binding to tyrosinase, which was confirmed by SPR (KD = 148 nM). Additionally, MALDI-MSI was employed for the first time to spatially map the distribution of bioactive triterpenoids directly in tissue, revealing that whitening-active LTDs , , and are widely distributed across different anatomical parts. This study establishes an integrated paradigm from structural discovery to spatial mapping for edible bioresource development. - Source: PubMed
Publication date: 2026/06/01
Yu YangLi Ting-TingDeng Zi-YiMa Si-QiTao Jun-ShiSun Yun-PengWang Guo-KaiWu De-LingLiu Jin-Song - Prostate cancer is the most common non-cutaneous malignancy in men and remains a leading cause of cancer-related mortality, particularly in aggressive variants. These tumors are usually associated with alterations in TP53, RB1, and PTEN. The microphthalmia-associated transcription factor (MITF) has been implicated in several malignancies, but its role in prostate cancer is less defined. - Source: PubMed
Pecorin Paul JDhliwayo NyembeziDemetrious MatthewCavalcante LudimilaRodriguez-Bravo VeronicaDomenech Josep DomingoWestbrook Thomas